7 Best ASX Stocks to Buy Now

5. Immutep Limited (NASDAQ:IMMP)

Number of Hedge Fund Holders: 2

Immutep Limited (NASDAQ:IMMP) is one of the 7 Best ASX Stocks to Buy Now. On June 23, Immutep Limited (NASDAQ:IMMP) announced positive initial efficacy data and continued favourable safety data from the placebo-controlled, double-blind first-in-human Phase I study evaluating IMP761. This is the first-in-class LAG-3 agonist antibody for autoimmune diseases. The company stated that through the highest dosing level to date (0.9 mg/kg of IMP761), there were no treatment-associated adverse events in healthy participants.

Considering the encouraging efficacy and safety, Immutep Limited (NASDAQ:IMMP) is continuing with single ascending dose levels of 2.5, 7, and 14 mg/kg. The LAG-3 (lymphocyte-activation gene-3) immune checkpoint is a promising therapeutic target for rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis in multiple publications. Immutep Limited (NASDAQ:IMMP) stated that IMP761 is the first LAG-3 agonist antibody developed for potentially treating these large and growing disorders, each of which showcases multi-billion-dollar markets, and several other autoimmune diseases.

Through enhancing the “brake” function of LAG-3 in order to silence the dysregulated self-antigen-specific memory T cells, IMP761 has been designed in a way that targets the cause of autoimmune diseases and restores balance to the immune system.

Immutep Limited (NASDAQ:IMMP) is a late-stage biotechnology company engaged in developing novel immunotherapies for cancer and autoimmune diseases.